FLT3 and acute myeloid leukemia: For example, for patients with FLT3-ITD-mutated AML, the FLT3 inhibitors gilteritinib, quizartinib, and sorafenib have all been found to improve patient outcomes as maintenance therapy after allo-HSCT in the r/r setting [83,84,85,86,87,88].